Eris Lifesciences (NSE:ERIS) Other Current Receivables: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ERIS Eris Lifesciences Ltd NSE:ERIS
93 GF Score
Price ₹1,354.70
GF Value ₹1,642.93
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eris Lifesciences Other Current Receivables?

Eris Lifesciences NSE:ERIS -1.49% 93 Other Current Receivables is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:ERIS with a GF Score™ of 93/100 and a GF Value™ of ₹1,642.93 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Eris Lifesciences's Other Current Receivables for the quarter that ended in Jun. 2026 was ₹0 Mil.

Eris Lifesciences's annual Other Current Receivables declined from Mar. 2024 (₹63.20 Mil) to Mar. 2025 (₹58.20 Mil) but then increased from Mar. 2025 (₹58.20 Mil) to Mar. 2026 (₹527.50 Mil).

Eris Lifesciences Other Current Receivables Related Terms

Eris Lifesciences Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Eris Lifesciences's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eris Lifesciences Other Current Receivables Chart

Eris Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 256.01 91.20 63.20 58.20 527.50

Eris Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 55.90 0.00 527.50 0.00
NSE:ERIS
93GF Score
Eris Lifesciences Ltd NSE:ERIS
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eris Lifesciences Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of ₹0 Mil mean?
Eris Lifesciences (NSE:ERIS) has a Other Current Receivables of ₹0 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Eris Lifesciences and its competitors.
Is Eris Lifesciences' Other Current Receivables too high?
Eris Lifesciences' current Other Current Receivables is ₹0 Mil. Overall, Eris Lifesciences has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' Other Current Receivables compare to ZTS?
Eris Lifesciences' Other Current Receivables of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Eris Lifesciences and its competitors. Eris Lifesciences's current Other Current Receivables is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (NSE:ERIS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,642.93, compared to a current price of ₹1,354.70 — trading 17.5% below its estimated fair value. The current Other Current Receivables is ₹0 Mil. Eris Lifesciences' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Eris Lifesciences (NSE:ERIS), the current Other Current Receivables is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eris Lifesciences (NSE:ERIS) Overvalued in 2026?

Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued. The current stock price of ₹1,354.70 is trading 17.5% below its estimated GF Value™ of ₹1,642.93. GuruFocus considers Eris Lifesciences to be Modestly Undervalued.

Key valuation signals for NSE:ERIS:

  • Other Current Receivables: ₹0 Mil
  • GF Value™: ₹1,642.93 vs. price of ₹1,354.70 (17.5% below fair value)
  • GF Score™: 93/100 with 6 warning signs

No single metric tells the full story. See the NSE:ERIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eris Lifesciences Business Description

Other Exchanges 540596:India
Address Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
93GF Score

Get the complete analysis for NSE:ERIS

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,354.70
Price
₹1,642.93
GF Value